ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Fennec Pharmaceuticals Inc. (FENC) stock surged +7.41%, trading at $5.94 on NASDAQ, up from the previous close of $5.53. The stock opened at $5.50, fluctuating between $5.50 and $5.96 in the recent session.
Research Triangle Park, NC 27709
United States
Website: https://www.fennecpharma.comContact: 919 636 4530Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Employees | 29 |
Beta | 0.36 |
Sales or Revenue | $21.64M |
5Y Sales Change% | 0% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |